Page last updated: 2024-11-05
thalidomide and Temporomandibular Disorders
thalidomide has been researched along with Temporomandibular Disorders in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Zanelatto, FB | 1 |
| Dias, EV | 1 |
| Teixeira, JM | 1 |
| Sartori, CR | 1 |
| Parada, CA | 1 |
| Tambeli, CH | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Analgesic Effects of Perioperative Propranolol Administration for Spine Surgery[NCT04421209] | Phase 2 | 0 participants (Actual) | Interventional | 2020-12-31 | Withdrawn (stopped due to No funding source) |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Other Studies
1 other study available for thalidomide and Temporomandibular Disorders